Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 20/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22975544 | 0.93 | NT5E (0.40) | NT5E | |
| SCHEMBL29616128 | 0.89 | NT5E (0.40) | NT5E | |
| SCHEMBL23006894 | 0.89 | NT5E (0.40) | NT5E | |
| SCHEMBL22614272 | 0.89 | NT5E (0.42) | NT5E | |
| SCHEMBL22614270 | 0.89 | NT5E (0.38) | NT5E | |
| SCHEMBL22975511 | 0.87 | NT5E (0.38) | NT5E | |
| SCHEMBL22975716 | 0.85 | PI4KA (0.38) | NT5E | |
| SCHEMBL23062619 | 0.85 | NT5E (0.40) | NT5E | |
| SCHEMBL22975486 | 0.85 | NT5E (0.51) | NT5E | |
| SCHEMBL23062625 | 0.84 | NT5E (0.47) | NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140979-A1 | HETEROCYCLIC INHIBITORS OF CD73 FOR TREATMENT OF DISEASE | TEON THERAPEUTICS, INC. | 2024-05-02 | — | — | US | disclosed |
| US-20240124512-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-04-18 | — | — | US | disclosed |
| WO-2024076872-A1 | HETEROCYCLIC INHIBITORS OF CD73 FOR TREATMENT OF DISEASE | TEON THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-11807658-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220411459-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2022-12-29 | — | — | US | disclosed |
| US-11530236-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| EP-4051688-A1 | CD73 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220220147-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2022-07-14 | — | — | US | disclosed |
| US-11325938-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11130778-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210214387-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-11028120-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20210130389-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210130390-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2021-05-06 | — | — | US | disclosed |
| WO-2021087136-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-3787635-A1 | CD73 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20210047359-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140979-A1 | HETEROCYCLIC INHIBITORS OF CD73 FOR TREATMENT OF DISEASE | ENTPD5, ENTPD1, ENTPD2 | NT5E 6/4885 |
| US-11028120-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-20240124512-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-11807658-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-20220220147-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-20220411459-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-11325938-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-11530236-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-20210130389-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-11130778-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-20210130390-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-20210047359-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-20210214387-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.